Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
RL Stone, AK Sood, RL Coleman - The lancet oncology, 2010 - thelancet.com
First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
RL Stone, AK Sood, RL Coleman - The Lancet. Oncology, 2010 - pubmed.ncbi.nlm.nih.gov
First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and
about 40-50% of women who respond to initial treatment relapse within 2 years. In the …
about 40-50% of women who respond to initial treatment relapse within 2 years. In the …
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
RL Stone, AK Sood, RL Coleman - The Lancet Oncology, 2010 - thelancet.com
First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
RL Stone, AK Sood, RL Coleman - The Lancet. Oncology, 2010 - europepmc.org
First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
[HTML][HTML] Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
RL Stone, AK Sood, RL Coleman - The lancet oncology, 2010 - ncbi.nlm.nih.gov
First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
Collateral damage: Toxic effects of targeted antiangiogenic therapies in ovarian cancer
RL Stone, AK Sood, RL Coleman - The Lancet Oncology, 2010 - pure.johnshopkins.edu
First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and
about 40-50% of women who respond to initial treatment relapse within 2 years. In the …
about 40-50% of women who respond to initial treatment relapse within 2 years. In the …
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
RL Stone, AK Sood, RL Coleman - The Lancet Oncology, 2010 - Elsevier
First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
Collateral damage: Toxic effects of targeted antiangiogenic therapies in ovarian cancer
RL Stone, AK Sood… - The lancet …, 2010 - mdanderson.elsevierpure.com
First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and
about 40-50% of women who respond to initial treatment relapse within 2 years. In the …
about 40-50% of women who respond to initial treatment relapse within 2 years. In the …
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
RL Stone, AK Sood, RL Coleman - The Lancet Oncology, 2010 - infona.pl
First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
RL Stone, AK Sood, RL Coleman - The Lancet. Oncology, 2010 - europepmc.org
First-line chemotherapy fails in more than 20% of patients with epithelial ovarian cancer and
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …
about 40–50% of women who respond to initial treatment relapse within 2 years. In the …